Semaglutide is a GLP-1 agonist created for Type 2 Diabetes and FDA approved in 2019. It was approved for the indication of weight loss as Wegovy in June 2021.
AVOID WHEN: History of Thyroid C-cell tumors; Pregnant; Breastfeeding; Trying to conceive; History of anorexia/bulimia
SIDE EFFECTS: Nausea (44%); Vomiting (25%); Diarrhea/GI distress (30%)
Tirzepatide
Tirzepatide is the newest form of weight loss medication. It was recently approved for Type 2 diabetes, and works through both the GLP-1 receptor and GIP receptors. Both of these work to slow stomach emptying and decrease appetite.
AVOID WHEN: Chronic malabsorption; Pregnancy; Cholestasis/History of Gallbladder disease; Pancreatitis; Family history of Thyroid Cancer; Thyroid disorders
SIDE EFFECTS: Nausea (44%); Vomiting (25%); Diarrhea/GI distress (30%)